Li-Fraumeni Syndrome (Germline TP53 Loss)

Status: draft · Last updated 2026-11-17 · By Jason S. Hauptman, MD, PhD (AI-assisted)

Read in the interactive book →

High-yield points

  • LFS = germline TP53, autosomal dominant; many cancers, frequent second malignancies .
  • CPC: about a third of tested children carry germline TP53. Test every child with CPC .
  • Childhood SHH medulloblastoma with chromothripsis points to TP53. Germline TP53 explains more than half of chromothripsis in SHH medulloblastoma .
  • LFS medulloblastoma does badly (5-year OS 23%), and radiotherapy improved survival in the largest cohort, the opposite of Gorlin syndrome .
  • Toronto surveillance (whole-body MRI, brain MRI, ultrasound) was associated with 5-year OS of 89% vs 60% among carriers who developed cancer (observational) .

Landmark papers

  • Toronto protocol (Villani et al., Lancet Oncol 2016): a prospective 11-year study of 89 TP53 carriers, 59 of whom underwent surveillance. Surveillance found 40 asymptomatic tumors in 19 of 59 patients (32%), and 5-year overall survival among carriers who developed cancer was 88.8% with surveillance vs 59.6% without (observational) .
  • 2023 AACR update (Achatz et al., Clin Cancer Res 2025): the Toronto protocol remains the standard for lifelong surveillance, with tests changing by age, organ by organ .

Li-Fraumeni syndrome (LFS) results from a germline pathogenic or likely pathogenic TP53 variant and is inherited in an autosomal dominant pattern .

Jason S. Hauptman, MD, PhD© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure from Hauptman's High Yield Thoughts in Pediatric Neurosurgery (pedsneurosurg.org). Do not copy, reproduce, redistribute or adapt without written permission.https://www.pedsneurosurg.org/hy-peds-ns:li_fraumeni:4bac65e39764f40c© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure; please do not copy, reproduce or redistribute without written permission.Core Li-Fraumeni tumors by age with pedigree symbols: adrenocortical carcinoma, choroid plexus carcinoma, SHH medulloblastoma, rhabdomyosarcoma, osteosarcoma, breast cancer, high-grade glioma and sarcoma; choroid plexus carcinoma in an infant lateral ventricle, SHH medulloblastoma with chromothripsis and high-grade glioma; and Toronto-protocol surveillance(A) CORE LFS TUMORS BY AGE (GERMLINE TP53)INFANCY / CHILDHOODADOLESCENCEADULTHOODadrenocorticalcarcinomachoroid plexuscarcinomaSHHmedulloblastomarhabdomyo-sarcomaosteosarcomabreastcancerhigh-gradegliomasoft-tissuesarcomaage(B) BRAIN TUMORS IN LFSchoroid plexus carcinomain the lateral ventricle(infant), hydrocephalusSHH medulloblastoma(TP53-mutant: poorprognosis)chromothripsis(shattered chromosome)older child: high-grade gliomarim enhancement(C) SURVEILLANCEToronto protocol: lifelong, age-adaptedwhole-body MRIbrain MRIabdominal/pelvicultrasoundminimize radiation
Li-Fraumeni syndrome. (a) Core tumors by age: adrenocortical carcinoma, choroid plexus carcinoma, SHH medulloblastoma and rhabdomyosarcoma in early childhood; osteosarcoma in adolescence; breast cancer, high-grade glioma and sarcoma in adults. (b) Brain tumors: choroid plexus carcinoma in an infant's lateral ventricle; SHH medulloblastoma with a shattered-chromosome (chromothripsis) icon; high-grade glioma in an older child. (c) Toronto-style surveillance: annual whole-body MRI, annual brain MRI, abdominal ultrasound, and minimizing ionizing radiation. Not to scale.

Brain tumors that should prompt TP53 testing

Medulloblastoma in LFS: treatment and outcome

Surveillance (the "Toronto protocol")

Practical points for the neurosurgeon

Related topics

References

  1. Achatz MI, Villani A, Bertuch AA, et al. Update on cancer screening recommendations for individuals with Li-Fraumeni syndrome. Clin Cancer Res 2025;31(10):1831–1840. doi:10.1158/1078-0432.CCR-24-3301. PMID 40072304. verified
  2. Gozali AE, Britt B, Shane L, et al. Choroid plexus tumors; management, outcome, and association with the Li-Fraumeni syndrome: the Children's Hospital Los Angeles (CHLA) experience, 1991–2010. Pediatr Blood Cancer 2012;58(6):905–909. doi:10.1002/pbc.23349. PMID 21990040. verified
  3. Waszak SM, Northcott PA, Buchhalter I, et al. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol 2018;19(6):785–798. doi:10.1016/S1470-2045(18)30242-030242-0). PMID 29753700. verified
  4. Rausch T, Jones DT, Zapatka M, et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 2012;148(1–2):59–71. doi:10.1016/j.cell.2011.12.013. PMID 22265402. verified
  5. Kolodziejczak AS, Guerrini-Rousseau L, Planchon JM, et al. Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. Neuro Oncol 2023;25(12):2273–2286. doi:10.1093/neuonc/noad114. PMID 37379234. verified
  6. Villani A, Shore A, Wasserman JD, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. Lancet Oncol 2016;17(9):1295–1305. doi:10.1016/S1470-2045(16)30249-230249-2). PMID 27501770. verified

Verification (2026-11-17):

Caveats: